Rejection Is Always Possible, but BioTransplant Could Take

BioTransplant(BTRN Quote), a tiny biotech firm based just outside Boston, is developing a novel treatment that "re-educates" a patient's immune system to combat cancer and a host of other diseases and which may also one day radically improve organ and tissue transplants.

Still, BioTransplant is flying below Wall Street's radar, thanks to the sagging biotech sector and the fact that much of its work is in early testing. Positive research results helped the shares jump 90% in two weeks, but the company still trades at around $6 per share, with a $70 million market capitalization -- a pittance compared to biotech's marquee names.

But the company is expected to report steady progress on its treatments in the coming months. Add that to a well-timed acquisition and a potentially lucrative alliance with another biotech drug maker, and BioTransplant may make some noise. ...